Genovate Biotechnology Co Ltd Cash Flow Quality Index
Genovate Biotechnology Co Ltd cash flow quality index. Genovate Biotechnology Co Ltd (4130) has a Cash Flow Quality Index of -3.61x as of June 2025. Operating cash flow of NT$-26.50 Million is below net income of NT$7.34 Million, suggesting accrual-heavy earnings not yet converted to cash. Explore debt repayment capacity of Genovate Biotechnology Co Ltd to assess how comfortably operating cash covers total debt obligations.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Cash Flow Quality Index of Genovate Biotechnology Co Ltd (2015–2025)
Cash flow quality index of Genovate Biotechnology Co Ltd from 2015 to 2025. Historical Cash Flow Quality Index for Genovate Biotechnology Co Ltd across 10 annual periods. Values consistently above 1.0x indicate high-quality earnings. See Genovate Biotechnology Co Ltd net asset quality index to measure how much of total assets are equity-financed.
Genovate Biotechnology Co Ltd Cash Flow Quality Index by Year (2015–2025)
Genovate Biotechnology Co Ltd cash flow quality index by year from 2015 to 2025. Year-by-year earnings quality comparison for Genovate Biotechnology Co Ltd. For the full cash flow conversion analysis, see 4130 cash flow conversion.
| Year | Quality Index | Operating CF (TWD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | 3.75x | NT$43.79 Million | NT$11.68 Million | ▲ +74.8% |
| 2024 | 2.14x | NT$55.11 Million | NT$25.70 Million | ▼ -25.8% |
| 2023 | 2.89x | NT$84.78 Million | NT$29.33 Million | ▲ +106.2% |
| 2021 | -46.40x | NT$-17.26 Million | NT$372.00K | ▼ -2163.6% |
| 2020 | 2.25x | NT$87.08 Million | NT$38.73 Million | ▲ +72.3% |
| 2019 | 1.30x | NT$44.43 Million | NT$34.05 Million | ▲ +20.0% |
| 2018 | 1.09x | NT$62.88 Million | NT$57.85 Million | ▲ +417.8% |
| 2017 | 0.21x | NT$31.27 Million | NT$148.97 Million | ▼ -88.3% |
| 2016 | 1.80x | NT$70.58 Million | NT$39.21 Million | ▲ +157.3% |
| 2015 | 0.70x | NT$32.53 Million | NT$46.49 Million | — |